Author(s): Neves, JM ; Cunha, N ; Lencastre, A ; Cabete, J
Date: 2022
Persistent ID: http://hdl.handle.net/10400.17/4441
Origin: Repositório do Centro Hospitalar de Lisboa Central, EPE
Subject(s): HSAC DER; Humans; Portugal; Adalimumab / therapeutic use; Anti-Inflammatory Agents / therapeutic use; Hidradenitis Suppurativa* / drug therapy; Severity of Illness Index; Tertiary Care Centers
